Background Advanced heart failure (HF) can be treated conservatively or aggressively, with left ventricular assist devices (LVADs) and heart transplant (HT) being the most aggressive strategies. Objective The goal of this review was to identify, describe, critique and summarize published cost-effectiveness analyses on LVADs for adults with HF. Methods We conducted a literature search using PubMed and ProQuest DIALOG databases to identify English-language publications from 2006 to 2017 describing cost-effectiveness analyses of LVADs and reviewed them against inclusion criteria. Those that met criteria were obtained for full-text review and abstracted if they continued to meet study requirements. Results A total of 12 cost-effectiveness studies (13 articles) were identified, all of which described models; they were almost evenly split between those examining LVADs as destination therapy (DT) or as bridge to transplant (BTT). Studies were Markov or semi-Markov models with one-or three-month cycles that followed patients until death. Inputs came from a variety of sources, with the REMATCH trial and INTERMACS registry common clinical data sources, although some publications also used data from studies at their own institutions. Costs were derived from standard sources in many studies but from individual hospital data in some. Inputs for health utilities, which were used in 11 of 12 studies, were generally derived from two studies. None of the studies reported a societal perspective, that is, included non-medical costs such as caregiving. Conclusions No study found LVADs to be cost effective for DT or BTT with base case assumptions, although incremental cost-effectiveness ratios met thresholds for cost effectiveness in some probabilistic analyses. With constant improvements in LVADs and expanding indications, understanding and re-evaluating the cost effectiveness of their use will be critical to making treatment decisions.
Introduction
More than a half million adults in the USA have been diagnosed with advanced heart failure (HF), in which the symptoms of heart failure can no longer be managed by medication and lifestyle changes [1] . As symptoms such as shortness of breath, chest pain, and fatigue become more frequent or severe, patients' quality of life deteriorates. Hospitalizations for HF are also associated with decrements in quality of life [2] . In the end stage of the disease, patients must consider whether they would like to be considered for aggressive therapies, such as receiving a left ventricular assist device (LVAD) or a heart transplant [3] .
Heart failure is the third most common cause of death attributable to coronary heart disease in the USA [1] . The cost of heart failure in the USA is substantial. By 2030, direct medical costs are expected to reach US$53 billion and indirect costs will reach US$17 billion [4] . This increase is driven by the aging of the population as well as an increase in the number of patients who receive implanted devices. Decision making for patients with advanced heart failure considers not only treatment costs, but also managing expectations and understanding the amount of available support and the extent of caregiver burden [5] . Difficult discussions about advance care planning are often necessary [6] . Patients with caregivers nearby and available to assist have better outcomes than patients without caregiver support [7] . Patients with advanced HF have expressed a preference for quality of life over quantity [8] . Despite the obvious importance of qualitative and humanistic inputs to selecting treatment for advanced HF, information on costs and cost effectiveness can contribute to treatment decisions.
LVADs have been in use since the 1960s [9] . Initially, they were provided as bridge to transplant (BTT) for patients awaiting available hearts. More recently, they have been made available as destination therapy (DT), bridge to candidacy until a patient becomes transplant eligible, or bridge to recovery, in which a patient may sufficiently improve to allow removal of the LVAD. Patients with these different indications can have dissimilar clinical profiles and their differences should be taken into consideration in evaluating the clinical appropriateness and cost effectiveness of LVADs.
The purpose of this review is to assemble and synthesize what is known about the cost effectiveness of LVAD for adults with advanced HF. As both the size of the HF population and the proportion of symptomatic patients for whom LVADs may be effective grow, it will become more important to consider cost effectiveness in making treatment decisions. We have limited the scope of this review to studies that are explicit in estimating cost effectiveness, that is, the cost per a specified unit of effectiveness such as life-year gained (LYG) or quality-adjusted life year (QALY).
Methods
We initially conducted a literature search using PubMed, which includes citations in MEDLINE, online books and life science journals; we repeated the search using the ProQuest DIALOG search service to identify articles in Embase. The search was limited to articles published in English-language journals from 2006 to 2017. A full listing of search terms and limiters is presented in Table 1 . Articles identified by the search were reviewed (JS) for evidence of primary data about the cost effectiveness of LVADs (i.e. not reviews, cost of illness studies, or mentions of costs only in passing).
At this stage, papers that appeared to meet inclusion criteria, or that could not be excluded based on the title and abstract review, were retrieved for a full-text review. Articles that were retrieved were reviewed by two co-authors (JS, ML) to determine relevance. Those that continued to meet inclusion criteria were abstracted by one reviewer (JS), with all fields checked by a second reviewer (ML) for quality control purposes.
In addition to the initial literature search in PubMed, we used a pearl-finding strategy, reviewing reference lists of identified articles and following suggestions about "related articles" in PubMed. This set of potential publications, having been identified based on the title and abstract appearing to warrant inclusion, essentially underwent only the full-text review.
A flow chart depicting counts at each stage, consistent with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, appears as Fig. 1 . The reviewed studies were evaluated using the Consolidated Health Economic Evaluation Reporting Standards (CHEERS) checklist [10] ; the evaluation is available as a supplementary online file (Electronic Supplementary Material A).
Results
The initial literature search identified 34 publications for title and abstract review after removal of the 10 duplicates identified in both PubMed and Embase. Figure 1 shows the counts of articles identified. Our pearl-finding review of reference lists and related articles yielded ten additional papers. The most common reasons for exclusion at the title and abstract review stage were not having a comparative component (i.e. a cost of illness study that did not compare interventions), being a review rather than having primary data, or reporting on a pediatric population. Of these studies, 13 met criteria for full review and abstraction; however, 2 reported on the same model [11, 12] . For the purpose of characterizing the literature, we refer to 12 unique studies, although there were 13 publications identified. Key information about each included study appears as Electronic Supplementary Material B.
Characterization of Studies
Of the 12 studies, 7 included LVAD as BTT in the analysis [11] [12] [13] [14] [15] [16] [17] [18] while LVAD as DT was explored by five [15, [19] [20] [21] [22] . The model by Long and colleagues explored pathways for patients who were eligible for transplant as well as those who were not [15] ; the model by Tadmouri and colleagues could not distinguish between LVAD as DT or BTT based on the limitations of the dataset used for clinical and cost inputs [23] . One study presented cost per LYG only [13] while all the other studies presented cost per QALY, some along with LYG [16, 19, 20, 22] . Eight of the analyses are Markov models and four are semi-Markov models. Six studies included a probabilistic analysis, although the willingness to pay (WTP) thresholds that were used varied and were not consistent with a specific evaluation framework [11, 17, 19, 20, 22, 23] .
Patient characteristics varied across studies, even within indications. Some models explicitly provided a starting age for the population; others provided the average ages from the studies from which clinical data were derived. For example, in the studies evaluating LVAD as BTT, Takura and colleagues used data from a study in which the average age was 38 years [18] while in the model by Neyt et al. the average age was 64 years [22] . Similarly, studies on LVAD as DT used data and modeled starting ages ranging from the 40s [21] to 70s [20] . Clinical characteristics also vary substantially, with studies reporting New York Heart Association (NYHA) functional class, Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) level, and United Network of Organ Sharing (UNOS) status. Further, inotrope-dependence, which has been considered as relevant to risk and outcomes, was specified in some studies but not in others. Thus, except for the studies that clearly build on each other, the ability to group studies by severity of HF of the target population is limited.
With one exception, models were designed to include patients' lifetimes. Takura and colleagues [18] modeled only out to 12 months with 36 months as a sensitivity analysis, while all the other studies modeled out to 20 years or the patients' lifetimes, though some shorter periods were considered in sensitivity analyses. The typical survival for The MeSH "heart failure" includes "heart failure, diastolic," "heart failure, systolic" and entry terms including "cardiac failure" and "heart decompensation." After the initial data abstraction, a confirmatory search including "cardiomyopathies" and "left ventricular dysfunction" was performed. These searches identified additional clinical papers. After requiring that a cost-related term was present, four additional papers were identified, none of which were cost-effectiveness analyses. Thus, the original search was determined to be adequate at identifying cost-effectiveness analyses and only the initial results are shown in the "cost-utility" OR "cost benefit analysis" OR "cost benefit") AND (effectiveness OR "cost effectiveness")) patients receiving LVAD as DT exceeds seven years [24] ; those who receive it as BTT often receive a transplant after approximately 4 months [25] . The length of cycles in the models was either one or three months. This influences the frequency of clinical transitions but also the precision around costs and utilities. It may also affect how costs and utilities are assigned if a patient does not survive the cycle. In terms of geography, half the studies were conducted in Europe (UK: five [11, 12, 14, 16, 17] ; Netherlands: one [22] ; France: one [23] ), one in Japan [18] and the rest in North America (USA: three [15, 19, 21] ; Canada: two [13, 20] ). The US studies seem to use a third-party payer perspective while the other studies use a government or societal perspective. One US study explicitly reports using a thirdparty payer perspective [21] ; the other two report a "societal" perspective but there is no evidence of indirect costs or outcomes (e.g. costs associated with mortality or lost productivity) included in the models [15, 19] . The choice of perspective is often driven by the audience for the analysis. Studies in the USA designed to convey information meaningful to commercial payers can reasonably defend a thirdparty payer perspective while studies aimed at audiences in other parts of the world are typically expected to incorporate indirect costs and societal costs.
The model by Pulikottil-Jacob and colleagues [17] was an extension of the model by Sharples [14] . The Clarke/ Sutcliffe model [11, 12] also used many of the same inputs as Sharples [14] from the Evaluation of Ventricular Assist Device Program UK (EVAD-UK).
Clinical Inputs

Findings
There are a limited number of sources for clinical data in this domain, much of which are derived from the prominent studies in the LVAD space-the INTERMACS registry and the REMATCH and HeartMate II Destination Therapy studies. The REMATCH trial evaluated use of LVADs as DT for patients with NYHA class IV; one-year survival for implanted patients was 52% [26] . The INTERMACS registry captures patients implanted with any FDA-approved device at a participating center since mid-2006; survival data are calculated by indication (BTT or DT) and era, to account for the introduction of new technologies [27] .
Complication rates differed substantially in the way in which they were handled and articulated in the models. Long et al. used an extensive list of complications at various time points to drive costs and, in many cases, decrements in quality of life [15] . The most common approach was for studies to implicitly consider complications in developing transition probabilities but not to present values directly [11, 13, 14, 16, 17, 21, 23] . Baras Shreibati et al. and Takura et al. presented input parameters for stroke as well as pump replacement [18, 19] . Chew and colleagues indirectly considered stroke in developing estimates for rate of rehospitalization and also considered device failure [20] ; Neyt et al. included rehospitalization [22] .
Implications
Given the few large influential studies in the LVAD space, one would expect similarities in clinical inputs across studies. Instead, analyses sometimes substitute selected variables from studies published by their own teams or conducted at their own healthcare facilities. Studies using their own center's data may have different results based on surgeon experience, facility practices, or small differences in patient risk profiles or selection criteria, each of which may affect outcomes. As the papers differ in how they present data, that is, some report transitions in three-month increments and others report annual values, it is difficult to compare inputs across studies and to be certain that data from the same study are used in the same way across studies.
The varied methods for incorporating complication data means that some of the models are much more flexible than others in responding to possible changes in complication rates. The model presented by Long et al. is more capable of identifying the impact of changes in complication rates than the other models, as it explicitly accounts for stroke, gastrointestinal bleed, infections, and pump failure associated with LVAD implant as well as HT [15] . Separating complications from survival is useful for evaluating different risk profiles.
Cost Inputs
Findings
There is an important difference between the DT and BTT population that can manifest in costs. For DT patients, once the LVAD is implanted, there can be readmissions and complications but not a second primary procedure. This translates to less variability across patient outcomes. For BTT patients, there can be mortality once the LVAD has been implanted but before a transplant is available. Thus, patients in BTT models can have costs for one or two procedures, particularly for the models in which the waiting period for a transplant is varied. The range of costs is likely to be greater, although one would anticipate that patients who receive an LVAD as BTT are expected to live until a heart is available.
There was a wide variety of types of costs included, with most studies including diagnostic and preparatory costs, hospitalization costs (index hospitalization and re-admissions), treatment of selected complications, and outpatient routine costs (assigned either monthly or quarterly). Few studies included anything other than direct medical resource utilization, with the possible exception of the study by Neyt et al., which includes "social work" and travel costs [22] . Tadmouri and colleagues did not include routine follow-up or professional fees [23] . Costs were derived from many sources, with several studies using multiple data sources, including national tariffs or data collection systems [14, 16, 22, 23] or Medicare [15, 19, 21] , one to five medical centers [13, 15, 17, 18, 20] , or primary micro-costing analysis [11, 23] . The Moreno study [16] used inflated values from the Sharples study [14] . It is unclear in many cases whether costs were billed amounts (charges) or reimbursed amounts.
Another cost input that varied widely across studies was routine outpatient costs associated with medical therapy after LVAD or HT. Many of the studies differentiated between costs in the immediate time after transplant or the first year versus subsequent years [15] ; some included distinct monthly costs for each month through six or more months [11, 14, 16, 17, 23, 28] . Given that the cost data were often derived from individual centers and small numbers of patients, there may be substantial variability in these estimates. Long-term survivors accrue costs for more months or cycles, but routine outpatient costs are only a small portion of overall costs and are subject to discounting over time. The impact of this variability across studies is uncertain; it may be insubstantial compared to operative costs. The range of estimates likely increases over time as the number of patients surviving decreases, that is, the long-term survivors are likely healthier, so the impact of this variability may be lessened.
No studies mentioned costs associated with mortality or lost productivity. While this is not unreasonable given the age of most HF patients, it does raise the question of whether these studies are essentially all that of a third-party payer, regardless of how they characterize their perspective, as well as whether these models and their findings are generalizable to younger adult populations. The geographic variation in study sites confounds evaluation of costs, as the relative contribution of different types of costs based on coverage policies and treatment patterns makes it challenging to compare directly across studies.
Studies used accepted practices for discounting based on local expectations, with rates varying from 1.5% to 5%. Discounting is the same for costs and outcomes within each study with the exception of Neyt et al. [22] , who discounted costs at 4% and outcomes at 1.5%. Variation in discounting has little impact on total costs when patients undergo a substantial intervention with a large cost at the start of an observation period. This is not always the case for LVAD implants. In some of these models, HT does not occur immediately but only after a patient spends some period of time on a waiting list, thus this large cost may appear later in the model and be more highly influenced by discounting.
Implications
One would expect such variability in the type and source of costs to result in similar variability in cost estimates, yet the inputs here, once inflated and converted into a common currency when possible, were remarkably similar, with most studies finding LVADs to be either not cost effective or have low value, that is, having incremental cost effectiveness of more than US$100,000/QALY. Some models found that the cost of implantation was a substantial source of uncertainty while others did not. Of the individual inputs to the models, the monthly routine outpatient costs appeared to be the most variable, but as these costs were much smaller than implantation or rehospitalization (even though they were accrued over patients' lifetimes), they likely had little effect on the overall model outcomes.
Over a short time period, inflating costs rather than identifying new values, whether from primary data analysis or national tariffs, may be reasonable. Once the gap exceeds five years, it becomes questionable whether it is appropriate to simply increase costs from a previous time period or to identify new costs. With advances in technologies and changes in practice patterns and coverage policies, earlier costs may no longer be representative. Thus, the series of studies that have loosely built upon and borrowed cost information from each other as updated clinical data were included may be missing an opportunity to maintain relevance by having inflated costs rather than obtaining current costs from primary sources.
There are two types of costs that were consistently excluded from these models: first, indirect costs such as mortality and lost productivity, and second, medical costs that were not directly related to the LVAD, HT, or routine medical therapy. The question of indirect costs is raised by the studies that state that they are using a societal perspective but show no evidence of any costs other than direct medical. A recent study of Danish patients diagnosed with HF found that one-fourth did not return to work after their first HF hospitalization [29] . While older age and comorbidities were associated with not returning to work, other factors such as sex and education also influenced return to work; simply suggesting that most patients who do not return to work may have been planning to retire regardless is insufficient. Given that indirect costs may represent as much as half of total costs of HF overall [4] , excluding them may underestimate cost effectiveness; whether indirect costs are substantially different for LVAD patients is not yet understood.
It is unclear whether potentially higher treatment costs for unrelated comorbid conditions were included in any of these models. For instance, a study of patients with HF who underwent bariatric surgery found that the length of hospitalization and the likelihood of requiring extensive ventilation were both higher in patients with HF than without [30] . Patients with HF undergoing total knee arthroplasty (TKA) also were found to have longer hospital stays and more readmissions [31] . Thus, for HF patients who undergo further surgeries for other indications, there may be higher costs. While the decision to perform TKA on a patient with HF may be complex, it is possible that the benefits of successful management of HF with an LVAD may minimize some of these additional costs and thus tighten the costeffectiveness calculations over time. An explicit evaluation of these peripheral potential savings could be meaningful, although a claims-based analysis may need to be conducted in order to derive inputs.
Utility Inputs
Findings
One area of agreement across much of the literature identified in this search is the use of a single study being used for many of the estimates of health utilities. Gohler et al. [32] used the EQ-5D, a generic measure of health status, to estimate utilities associated with NYHA class based on patients in the EPHESUS trial. These patients were randomized to eplerenone or placebo after myocardial infarction. Less than 10% had a previous hospitalization for heart failure. This study is widely cited throughout the literature on utilities in heart failure. Chew et al. [20] and Rogers et al. [21] use the same utility values and Clarke et al. [11] and Tadmouri et al. [23] use the same values, all directly from or derived from Gohler's study [32] . However, other sources were repeated in the papers in this review. Sharples [14] , Moreno [16] and Long [15] used almost identical values. Neyt and colleagues used values for their analysis of LVAD-DT [22] from a study using a standard gamble among LVAD-BTT patients published almost 20 years earlier [33] ; Takura collected EQ-5D scores directly from patients [18] . Despite the dominance of the NYHA-based Gohler et al. estimates, there was wide variation in the utility values appearing in the models, as shown in Table 2 .
Implications
Despite there being only a few sources for utilities, these variations in input values are large (see Table 2 ) and have important implications for the models. The difference in total accrued QALYs between groups over the study period ranged from 0.005 in a study that did not differentiate between DT and BTT but used among the highest values for utility inputs [23] to 7.09 in a study comparing lifetime medical therapy with immediate HT that used lower values for utility inputs [15] .
While the use of the utility estimates from the Gohler study provides continuity across studies, there are many problems inherent with the use of the data. The comparability of the EPHESUS patient population with patients eligible for LVADs is questionable, even though the data are presented as utilities by NYHA class, often considered universally meaningful for cardiovascular disease patients. Further, there are recent data that suggest the EQ-5D is less sensitive than a disease-specific instrument [34] and perhaps less than other generic instruments [35] . Models using data from the Gohler EQ-5D NYHA class calculations may be underestimating the impact of the LVAD-related health states.
However, there are still important differences in assumptions, particularly in those separate from NYHA category classification. The entry to the model, often a waiting period to transplant or a medical therapy state, has utilities assigned ranging from 0.40 [19] to 0.548 [22] ; a post-stroke state was assigned a value of 0.30 [19] and one twice as high (0.68) [15] . The differences in utility values assigned following LVAD implant have a fairly tight range, after the initial cycle, which could be lower, with values ranging from 0.66 to 0.75. Further while discounting accounts for some expected deterioration over time, it does not account sufficiently for age or comorbidities in this typically older population, nor did any of the models discuss decrease in utilities (or increase in cost) associated with the last year of life.
Cost Effectiveness: Comparative Findings
In order to compare findings, we used the cost per QALY recommendations of the American Heart Association and American College of Cardiology (AHA/ACC), in which < US$50,000/QALY is high value, ≥ US$150,000 is low value, and between the two represents intermediate value [36, 37] . This framework allows for higher costs per QALY than the original values promulgated decades ago, which have recently been acknowledged to be too rigid for continued use [28] . Other countries' thresholds for cost effectiveness differ from the AHA/ACC so that using their guidelines would sometimes change assessments. For example, many countries' thresholds for cost effectiveness are based on the per capita GDP and differ dramatically from each other [38] . For reference, the threshold beyond which additional support is requested in the UK is £30,000, but in the UK, as in other countries, there may be allowances for age, severity, or other characteristics of the disease or patient [38] . We present the AHA/ACC guidelines because they are specific to cardiac care and most of the studies reviewed already provided results in US$.
There were, as discussed earlier, few studies that are generally comparable and have a great deal of heterogeneity in study design. After converting and inflating currency to US$2017 for the studies that stated the year in which results were presented, LVAD as DT compared to medical therapy was estimated as not meeting the threshold for low value for cost effectiveness (ranging from approximately US$175,000 to US$233,000 per QALY [15, [19] [20] [21] ). Probabilistic analyses using various WTP thresholds of US$150,000/QALY or less found LVAD to DT cost effective less than half of the time (cost effective 44% of the time at the threshold [20, 21] of US$150K/QALY in US$ among low-risk patients [19] , 51% of the time at a threshold of CAN$230,000/QALY [20] , 16% of the time at a threshold of EUR80,000/QALY [22] . Although most models were sensitive to survival and/ or costs, their structures and inputs were different enough that it is not possible to declare that the cost effectiveness of LVADs as DT is sensitive to any particular input more than another. LVAD as BTT was associated with a wider set of results, with studies finding intermediate or low value or perhaps not being cost effective (in 2017 US$, approximately US$82,000 [11, 12] , US$89,000 [14] , US$144,000 [16] , and US$241,000 [15] per QALY). The study looking at cost/QALY in 12 or 36 months also found it not to be cost effective, but the short follow-up duration makes it difficult to compare [18] . The study comparing two devices found that the HeartWare was very cost effective compared to the HeartMate II (cost/QALY in 2017 less than US$36,000), although the study did not compare the devices against medical therapy [17] . Cost inputs can vary substantially by country and our attempt to aggregate by using a common currency should be considered cautiously. Our aggregation did not assign new costs based on a US standard but simply used the studies' reported cost-effectiveness findings and expressed them in US dollars. As an alternative, considering the range of findings for the probabilistic sensitivity analyses may be useful. Of these studies, three evaluated DT [19, 20, 22] , one evaluated BTT [11] , and one included patients with either indication [23] . No two studies presented likelihood of cost effectiveness using the same two WTP thresholds, complicating the ability to align findings for comparison.
Discussion
One obvious question is whether there are key input parameters that are consistently influential across the reviewed studies and, in a larger sense, relevant to understanding cost effectiveness with LVADs. Based on the heterogeneity across the studies included in the review, this remains unclear, as there was no input parameter that stood out as influencing model outcomes more often than others. Given the variety of methods used to operationalize each input (i.e. whether costs included professional fees, or if all-cause admissions were included or only HF re-admissions), even models that appear to be sensitive to the same inputs, under careful scrutiny, may not be. While survival is included in many of the sensitivity analyses, it is not clear how authors selected which analyses to conduct. For example, it is not clear that Long and colleagues [15] examined uncertainty around cost inputs and while Rogers and colleagues [21] conducted extensive sensitivity analyses around utility values, they do not seem to have conducted analyses around most of the cost inputs. Thus, understanding the extent to which input parameters influence the findings is not easy. While probabilistic sensitivity analyses may implicitly explore multiple inputs, it does not typically provide insight on the importance of specific inputs. Given the pace of advances in LVAD technology and changes in care, such as a decrease in the cost of hospitalizations in the USA in recent years [39] , it seems important to understand the influence of inputs that are likely to change.
These models consider only the cost of medical treatment for LVAD recipients. They do not consider the caregivers or any non-medical costs. Patient quality of life is theoretically inherently captured with health state utilities, yet there is evidence that there is a substantial quality of life impact on caregivers that is rarely quantified [40] . Studies that have explored quality of life for patients and caregivers suggest that the trajectory may be more complex than the economic models have considered [41] . As indications for LVADs expand and younger patients may receive them, estimating lost productivity will likely become more relevant.
There may be other relevant subgroup analyses that none of the models have addressed. Some of these analyses are related to characteristics of care and others to patient characteristics. For example, for BTT patients, a recent study did not find differences in long-term survival after transplant associated with the duration of the LVAD support but did find that lead infections and transfusions were associated with survival [42] . There may be a window for optimal timing of transplant after LVAD implantation [43] . The model by Moreno and colleagues compared outcomes by the duration of the wait for transplant [16] ; other studies did not consider timing as explicitly. Outcomes and costs may also be influenced by the practice of delayed versus sternal closure [44] . The type and intensity of inpatient rehabilitation may be associated with outcomes [45, 46] but no information on rehabilitation programs was provided in the reviewed studies to allow for its consideration in models.
Demographic and non-cardiovascular clinical characteristics may also be relevant. A study comparing complications among patients who received continuous-flow LVADs found that while mortality was similar among men and women, women had higher rates of multiple complications [47] . None of the models identified sex as an important input variable, but if complication rates and related costs associated with treating those complications vary between men and women, this may be an important factor to consider in cost-effectiveness evaluation. Patients in these models were characterized by cardiac function but not by frailty, yet frailty may be an important predictor of outcomes [48] . Hospital costs in HF may be influenced by depression and race/ethnicity [49] , information that was likely not available in the source data used to populate these models.
Limitations
The search strategy is both a limitation and a crucial constraint on analyses. For example, there were several studies published in the years immediately before the start of the search period, but many appeared to review cost effectiveness of first-generation LVADs. Given the technological advances implemented for the second-and third-generation devices, the starting point for the search helped to minimize variation in devices and therefore other model inputs. Limiting to English-language studies may have eliminated publications that would otherwise have been included, although variation in treatment patterns in a study that was published in a non-English journal may have been substantial and limited interpretability regardless. The search was augmented by review of reference lists, providing another avenue for identifying articles and ensuring opportunities to find all relevant studies.
During the initial identification of literature, there was some concern about the small number of studies identified. However, subsequent adjustment of the search terms did not yield additional studies. Further, the existing published reviews of ventricular assist devices, although from slightly earlier time periods, did not yield substantially different counts. Nunes and colleagues included ten studies of moderate or better quality in English on mechanical circulatory support [50] ; since the publication, multiple cost-effectiveness analyses of LVAD as DT have been published. Neyt and colleagues included seven publications in their work [51] but limited the search to destination therapy. They included cost-effectiveness analyses but also a study on value-based reimbursement [52] that did not qualify for inclusion under the current search strategy.
There was no a priori plan for using a checklist, such as the Consolidated Health Economic Evaluation Report Standards (CHEERS) tool, to evaluate the literature. Had the goal of this effort been to conduct a meta-analysis, use of a quality checklist would have been necessary. However, our objective was to understand both the state of the science in terms of cost-effectiveness of LVADs as well as the state of the science in terms of the tools used to make that assessment. Being able to review and present a wide variety of models with various inputs provides insight into cost effectiveness as well as the usefulness of existing scholarship. In turn, the assessments that can be made can be valuable to designing newer models. With the variability in models and lack of generalizability, a meta-analysis seems improbable at best. This is not to imply that none of the identified studies are of sufficient quality to contribute to our understanding of the cost effectiveness of LVADs; we have pointed out a number of flaws or omissions.
Finally, the inherent design differences between continuous and pulsatile LVADs may lead to disparities in myocardial remodeling and LV function recovery. These differences and their impact on cost effectiveness were not captured in our analysis as the publications did not consistently report the type of LVAD, nor did they report on outcomes with the granularity to articulate these additional disparities. However, with a clear shift towards continuous flow LVADs, teasing out differences in pulsatile and continuous flow devices may be a futile exercise.
Considerations for Future Research
Reviews on LVADs [53] [54] [55] [56] , the present one included, have found a great deal of heterogeneity across studies. There is also aggregating across indications, incomplete reporting, site-specific costing, inaccurate claims of societal perspectives, and references to secondary sources rather than primary sources. Remarkably, although sensitivity analyses find different factors strongly influencing each model, there is overall consistency. It is evident after adjusting the costs to a common currency and year, that the use of LVADs has not, in recent history, met standards for moderate cost effectiveness as defined by the AHA and ACC [36, 37] .
As LVAD technology advances beyond the third generation, there is, however, potential for LVADs to become cost effective. Next generation LVADs will likely be more durable, reliable, and smaller in size, allowing the possibility of implantation using minimally invasive techniques (e.g. transcatheter procedure), potentially reducing procedure costs, length of stay and complication rates. Improvements in technology may result in lower rates of long-term adverse events and complications (e.g. reoperation for pump replacement, stroke, infection) and hospital readmission, and consequently improve patient survival and quality of life. These potential cost savings may be offset by possible increased cost of the new device technology. With continued improvements in LVAD technology (e.g. continuous vs pulsatile flow), changes in patient selection and clinical management strategies, and expanded indications for LVADs, the cost effectiveness of these devices should be re-evaluated in the future.
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